Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IDegAsp vs Basal-Bolus in T1DM
NCT04965051Unknown
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Aug 2021
- Primary completion
- Dec 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, open-label trial of insulin degludec + insulin aspart in type 1 diabetes mellitus (T1D) (2 arms), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: Change from baseline in HbA1c at 16 weeks. Status: unknown.
02
Drugs
insulin degludec + insulin aspart
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT04965051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04965051.